TABLE 1.

Sample information^a

Study code	Sample/references ampoule code	Description
A	06/140	Freeze-dried preparation of “high” anti-PT IgG content human serum
B	06/142	Freeze-dried preparation of “low” anti-PT IgG content human serum
C	06/144	Freeze-dried preparation of “low” anti-PT IgG content human serum
D	06/146	Freeze-dried preparation of “high” anti-PT IgG content human serum
E	PM-06-047	Baseline control serum; freeze-dried preparation of human serum with “undetectable” IgG anti-PT content
U.S. lot 3		U.S. reference pertussis antiserum (human) lot 3; freeze-dried reference preparation of serum with the following units: IgG anti-PT (200 EU/ml); IgA anti-PT (15 EU/ml); IgG FHA (200 EU/ml); and IgA FHA (100 EU/ml)
U.S. lot 4		U.S. reference pertussis antiserum (human) lot 4; freeze-dried reference preparation of serum with the following units: IgG anti-PRN (90 EU/ml) and IgA anti-PRN (25 EU/ml)
U.S. lot 5		U.S. reference pertussis antiserum (human) lot 5; a secondary reference with units assigned based on U.S. lots 3 and 4: IgA anti-PT (140 EU/ml); IgA anti-FHA (280 EU/ml); and IgA anti-PRN (90 EU/ml)

^aFor use in assays, all preparations were reconstituted with 1.0 ml of sterile water.